<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 07 Nov 2024 00:51:02 +0000</lastbuilddate>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>The ESC Textbook of Heart Failure: breaking the new educational frontier</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 6:ehad897. doi: 10.1093/eurheartj/ehad897. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39504565</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad897>10.1093/eurheartj/ehad897</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504565</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Petar M Seferovic</dc:creator>
<dc:creator>Andrew J S Coats</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The ESC Textbook of Heart Failure: breaking the new educational frontier</dc:title>
<dc:identifier>pmid:39504565</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad897</dc:identifier>
</item>
<item>
<title>Hypertrophic cardiomyopathy evolving management: American Heart Association/American College of Cardiology vs. European Society of Cardiology guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 6:ehae507. doi: 10.1093/eurheartj/ehae507. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39504436</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae507>10.1093/eurheartj/ehae507</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504436</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Edoardo Bertero</dc:creator>
<dc:creator>Marco Canepa</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hypertrophic cardiomyopathy evolving management: American Heart Association/American College of Cardiology vs. European Society of Cardiology guidelines</dc:title>
<dc:identifier>pmid:39504436</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae507</dc:identifier>
</item>
<item>
<title>Distinct Genetic Risk Profile in Aortic Stenosis Compared With Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504041/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This GWAS adjusted for CAD found a distinct genetic risk profile for AS at the single-marker and polygenic level. These findings provide new targets for future AS research.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 6. doi: 10.1001/jamacardio.2024.3738. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist. However, it is unknown which genetic and cardiovascular risk factors might be AS-specific and which could be shared between AS and CAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To identify genetic risk loci and cardiovascular risk factors with AS-specific associations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a genomewide association study (GWAS) of AS adjusted for CAD with participants from the European Consortium for the Genetics of Aortic Stenosis (EGAS) (recruited 2000-2020), UK Biobank (recruited 2006-2010), Estonian Biobank (recruited 1997-2019), and FinnGen (recruited 1964-2019). EGAS participants were collected from 7 sites across Europe. All participants were of European ancestry, and information on comorbid CAD was available for all participants. Follow-up analyses with GWAS data on cardiovascular traits and tissue transcriptome data were also performed. Data were analyzed from October 2022 to July 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Genetic variants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cardiovascular traits associated with AS adjusted for CAD. Replication was performed in 2 independent AS GWAS cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 18 792 participants with AS and 434 249 control participants were included in this GWAS adjusted for CAD. The analysis found 17 AS risk loci, including 5 loci with novel and independently replicated associations (RNF114A, AFAP1, PDGFRA, ADAMTS7, HAO1). Of all 17 associated loci, 11 were associated with risk specifically for AS and were not associated with CAD (ALPL, PALMD, PRRX1, RNF144A, MECOM, AFAP1, PDGFRA, IL6, TPCN2, NLRP6, HAO1). Concordantly, this study revealed only a moderate genetic correlation of 0.15 (SE, 0.05) between AS and CAD (P = 1.60 × 10-3). Mendelian randomization revealed that serum phosphate was an AS-specific risk factor that was absent in CAD (AS: odds ratio [OR], 1.20; 95% CI, 1.11-1.31; P = 1.27 × 10-5; CAD: OR, 0.97; 95% CI 0.94-1.00; P = .04). Mendelian randomization also found that blood pressure, body mass index, and cholesterol metabolism had substantially lesser associations with AS compared with CAD. Pathway and transcriptome enrichment analyses revealed biological processes and tissues relevant for AS development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This GWAS adjusted for CAD found a distinct genetic risk profile for AS at the single-marker and polygenic level. These findings provide new targets for future AS research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504041/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39504041</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3738>10.1001/jamacardio.2024.3738</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504041</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Teresa Trenkwalder</dc:creator>
<dc:creator>Carlo Maj</dc:creator>
<dc:creator>Baravan Al-Kassou</dc:creator>
<dc:creator>Radoslaw Debiec</dc:creator>
<dc:creator>Stefanie A Doppler</dc:creator>
<dc:creator>Muntaser D Musameh</dc:creator>
<dc:creator>Christopher P Nelson</dc:creator>
<dc:creator>Pouria Dasmeh</dc:creator>
<dc:creator>Sandeep Grover</dc:creator>
<dc:creator>Katharina Knoll</dc:creator>
<dc:creator>Joonas Naamanka</dc:creator>
<dc:creator>Ify R Mordi</dc:creator>
<dc:creator>Peter S Braund</dc:creator>
<dc:creator>Martina Dreßen</dc:creator>
<dc:creator>Harald Lahm</dc:creator>
<dc:creator>Felix Wirth</dc:creator>
<dc:creator>Stephan Baldus</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Moritz von Scheidt</dc:creator>
<dc:creator>Johannes Krefting</dc:creator>
<dc:creator>David Ellinghaus</dc:creator>
<dc:creator>Aeron M Small</dc:creator>
<dc:creator>Gina M Peloso</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>George Thanassoulis</dc:creator>
<dc:creator>James C Engert</dc:creator>
<dc:creator>Line Dufresne</dc:creator>
<dc:creator>Andre Franke</dc:creator>
<dc:creator>Siegfried Görg</dc:creator>
<dc:creator>Matthias Laudes</dc:creator>
<dc:creator>Ulrike Nowak-Göttl</dc:creator>
<dc:creator>Mariliis Vaht</dc:creator>
<dc:creator>Andres Metspalu</dc:creator>
<dc:creator>Monika Stoll</dc:creator>
<dc:creator>Klaus Berger</dc:creator>
<dc:creator>Costanza Pellegrini</dc:creator>
<dc:creator>Adnan Kastrati</dc:creator>
<dc:creator>Christian Hengstenberg</dc:creator>
<dc:creator>Chim C Lang</dc:creator>
<dc:creator>Thorsten Kessler</dc:creator>
<dc:creator>Iiris Hovatta</dc:creator>
<dc:creator>Georg Nickenig</dc:creator>
<dc:creator>Markus M Nöthen</dc:creator>
<dc:creator>Markus Krane</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:creator>Nilesh J Samani</dc:creator>
<dc:creator>Johannes Schumacher</dc:creator>
<dc:creator>Mart Kals</dc:creator>
<dc:creator>Anu Reigo</dc:creator>
<dc:creator>Maris Teder-Laving</dc:creator>
<dc:creator>Jan Gehlen</dc:creator>
<dc:creator>Thomas R Webb</dc:creator>
<dc:creator>Ann-Sophie Giel</dc:creator>
<dc:creator>Laura L Koebbe</dc:creator>
<dc:creator>Nina Feirer</dc:creator>
<dc:creator>Maximilian Billmann</dc:creator>
<dc:creator>Sundar Srinivasan</dc:creator>
<dc:creator>Sebastian Zimmer</dc:creator>
<dc:creator>Colin N A Palmer</dc:creator>
<dc:creator>Ling Li</dc:creator>
<dc:creator>Chuhua Yang</dc:creator>
<dc:creator>Oleg Borisov</dc:creator>
<dc:creator>Matti Adam</dc:creator>
<dc:creator>Verena Veulemans</dc:creator>
<dc:creator>Michael Joner</dc:creator>
<dc:creator>Erion Xhepa</dc:creator>
<dc:creator>TARGET Consortium; Estonian Biobank; and the European Consortium for Genetics of Aortic Stenosis (EGAS)</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Distinct Genetic Risk Profile in Aortic Stenosis Compared With Coronary Artery Disease</dc:title>
<dc:identifier>pmid:39504041</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3738</dc:identifier>
</item>
<item>
<title>Heart Failure With Preserved Ejection Fraction-A Role for Invasive Hemodynamics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504035/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 6. doi: 10.1001/jamacardio.2024.3764. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504035/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39504035</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3764>10.1001/jamacardio.2024.3764</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504035</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>James E Udelson</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Heart Failure With Preserved Ejection Fraction-A Role for Invasive Hemodynamics</dc:title>
<dc:identifier>pmid:39504035</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3764</dc:identifier>
</item>
<item>
<title>The Role of Fat in Frailty Assessment Before Transcatheter Aortic Valve Replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 6. doi: 10.1001/jamacardio.2024.3822. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39504011</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3822>10.1001/jamacardio.2024.3822</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504011</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Alberto Somaschini</dc:creator>
<dc:creator>Amanda Casirati</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>The Role of Fat in Frailty Assessment Before Transcatheter Aortic Valve Replacement</dc:title>
<dc:identifier>pmid:39504011</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3822</dc:identifier>
</item>
<item>
<title>Disease Drivers in Aortic Stenosis vs Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 6. doi: 10.1001/jamacardio.2024.3749. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39504008</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3749>10.1001/jamacardio.2024.3749</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504008</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Mark C Blaser</dc:creator>
<dc:creator>Elena Aikawa</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Disease Drivers in Aortic Stenosis vs Atherosclerosis</dc:title>
<dc:identifier>pmid:39504008</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3749</dc:identifier>
</item>
<item>
<title>Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504003/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: The findings suggest that HFpEF is underdiagnosed and should be rigorously evaluated for in patients with severe isolated STR, along with precapillary PH, as both have distinct requirements for management. Resting DD based on current guidelines is insufficiently sensitive in these patients, indicating a pressing need for other noninvasive diagnostic tools, such as left atrial function assessment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 6. doi: 10.1001/jamacardio.2024.3767. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Secondary tricuspid regurgitation (STR) is observed in multiple cardiac and pulmonary diseases. Heart failure with preserved ejection fraction (HFpEF) is a common cause of STR that may be overlooked, along with precapillary etiologies of pulmonary hypertension (PH).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To investigate the prevalence of HFpEF and precapillary PH in patients with severe STR of undefined etiology (isolated STR) referred for exercise right heart catheterization (RHC), and to evaluate the performance of noninvasive measures to identify HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This retrospective cross-sectional study included consecutive adults with severe STR in the absence of EF less than 50%, hemodynamically significant left-sided valve disease, congenital heart disease, infiltrative or hypertrophic cardiomyopathy, pericardial disease, or prior cardiac procedures who underwent rest-and-exercise RHC between February 2006 and June 2023 at Mayo Clinic and transthoracic echocardiography less than 90 days prior. Diastolic dysfunction (DD) was defined by at least 3 of 4 or 2 of 3 abnormal diastolic parameters (medial e', medial E/e', tricuspid regurgitation [TR] velocity, left atrial volume index). HFpEF was diagnosed when pulmonary arterial wedge pressure was at least 15 mm Hg at rest, at least 19 mm Hg with feet up, or at least 25 mm Hg during exercise. Data analysis was performed from November 2023 to March 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The prevalence of HFpEF and precapillary PH in severe isolated STR was determined, and performance of noninvasive measures to identify HFpEF was evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 54 patients with severe isolated STR (mean [SD] age, 70.8 [12.5] years; 34 [63%] female) were identified. The primary indication for RHC was evaluation of TR prior to potential intervention in 36 patients (67%), evaluation of PH in 13 (24%), and confirmation of HFpEF in 5 (9%). HFpEF was identified in 40 patients (74%) but was recognized prior to RHC in only 19 patients (35%). Of the 14 remaining patients without HFpEF, precapillary PH was diagnosed in 10 (71%). Guideline-defined DD was absent in 24 patients (60%) who were subsequently diagnosed with HFpEF. Left atrial emptying fraction (area under the receiver operating characteristic curve [AUC] = 0.90; 95% CI, 0.82-0.98) and strain (AUC = 0.91; 95% CI, 0.83-0.99) had robust discrimination for HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The findings suggest that HFpEF is underdiagnosed and should be rigorously evaluated for in patients with severe isolated STR, along with precapillary PH, as both have distinct requirements for management. Resting DD based on current guidelines is insufficiently sensitive in these patients, indicating a pressing need for other noninvasive diagnostic tools, such as left atrial function assessment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504003/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39504003</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3767>10.1001/jamacardio.2024.3767</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504003</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jwan A Naser</dc:creator>
<dc:creator>Tomonari Harada</dc:creator>
<dc:creator>Yogesh N Reddy</dc:creator>
<dc:creator>Sorin V Pislaru</dc:creator>
<dc:creator>Hector I Michelena</dc:creator>
<dc:creator>Christopher G Scott</dc:creator>
<dc:creator>Austin M Kennedy</dc:creator>
<dc:creator>Patricia A Pellikka</dc:creator>
<dc:creator>Vuyisile T Nkomo</dc:creator>
<dc:creator>Mackram F Eleid</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation</dc:title>
<dc:identifier>pmid:39504003</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3767</dc:identifier>
</item>
<item>
<title>Screening for Abdominal Aortic Aneurysms Still Prevents Ruptures: A Secondary Analysis of the VIVA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39503656/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)08463-8. doi: 10.1016/j.jacc.2024.09.011. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39503656/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39503656</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.011>10.1016/j.jacc.2024.09.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39503656</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Marie Dahl</dc:creator>
<dc:creator>Mads Liisberg</dc:creator>
<dc:creator>Margrete Stenehjem</dc:creator>
<dc:creator>Islam Al Obeidi</dc:creator>
<dc:creator>Jes Sanddal Lindholt</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Screening for Abdominal Aortic Aneurysms Still Prevents Ruptures: A Secondary Analysis of the VIVA Trial</dc:title>
<dc:identifier>pmid:39503656</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.011</dc:identifier>
</item>
<item>
<title>Classification of Myocardial Infarction in Women With Hypertensive Disorders of Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39503655/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 1:S0735-1097(24)09773-0. doi: 10.1016/j.jacc.2024.07.058. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39503655/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39503655</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.058>10.1016/j.jacc.2024.07.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39503655</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Classification of Myocardial Infarction in Women With Hypertensive Disorders of Pregnancy</dc:title>
<dc:identifier>pmid:39503655</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.058</dc:identifier>
</item>
<item>
<title>Sudden Death in Obesity: Mechanisms and Management</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39503654/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>In recent decades, the prevalence of obesity has increased significantly, leading to an epidemic at the global level. Obesity is associated with various metabolic alterations and increases the risk of cardiovascular disease. The most devastating manifestation of cardiovascular disease is sudden cardiac death (SCD), leading to substantial years of potential life lost worldwide. Obesity-related SCD is an increasingly important public health problem and warrants a specific investigative focus on...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 25:S0735-1097(24)08510-3. doi: 10.1016/j.jacc.2024.09.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In recent decades, the prevalence of obesity has increased significantly, leading to an epidemic at the global level. Obesity is associated with various metabolic alterations and increases the risk of cardiovascular disease. The most devastating manifestation of cardiovascular disease is sudden cardiac death (SCD), leading to substantial years of potential life lost worldwide. Obesity-related SCD is an increasingly important public health problem and warrants a specific investigative focus on improved risk stratification and prevention. In this review, we summarize the current evidence regarding management of SCD in obesity and discuss knowledge gaps as well as future directions in this field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39503654/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39503654</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.016>10.1016/j.jacc.2024.09.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39503654</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lauri Holmstrom</dc:creator>
<dc:creator>Juhani Junttila</dc:creator>
<dc:creator>Sumeet S Chugh</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sudden Death in Obesity: Mechanisms and Management</dc:title>
<dc:identifier>pmid:39503654</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.016</dc:identifier>
</item>
<item>
<title>Hypertensive Disorders of Pregnancy Increase the Risk for Myocardial Infarction: A Population-Based Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39503653/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A history of HDP is associated with CAD earlier in life and with a future risk for myocardial infarction with both obstructive and nonobstructive coronary arteries. This study underscores the need for timely detection and treatment of nonobstructive disease, in addition to traditional risk factors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 2:S0735-1097(24)09771-7. doi: 10.1016/j.jacc.2024.06.049. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Angiographic evidence of the anatomy of coronary arteries and the type of coronary artery lesions in women with a history of hypertensive disorders of pregnancy (HDP) are poorly documented.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine the role of a history of HDP as a unique risk factor for early coronary artery disease (CAD) and type of acute coronary syndrome (ACS) (ie, atherosclerotic vs myocardial infarction with nonobstructive coronary arteries [MINOCA]) in women who underwent coronary angiography.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study used a population-based cohort of parous female patients with incident CAD who underwent coronary angiography and age-matched control subjects. The SYNTAX (Synergy between PCI [percutaneous coronary intervention] with TAXUS [Boston Scientific] and Cardiac Surgery) score was assessed to determine the complexity and degree of CAD; MINOCA was diagnosed in the presence of clinical acute myocardial infarction in the absence of obstructive coronary disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 506 parous female Olmsted County, Minnesota (USA) residents had incident CAD and angiographic data from November 7, 2002 to December 31, 2016. Women with HDP were younger than normotensive women at the time of the event (median: 64.8 years vs 71.8 years; P = 0.030). There was a strong association between HDP and ACS (unadjusted P = 0.018). Women with HDP compared with women with normotensive pregnancies were more likely to have a higher SYNTAX score (OR: 2.28; 95% CI: 1.02-5.12; P = 0.046), and MINOCA (OR: 2.08; 95% CI: 1.02-4.25; P = 0.044).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A history of HDP is associated with CAD earlier in life and with a future risk for myocardial infarction with both obstructive and nonobstructive coronary arteries. This study underscores the need for timely detection and treatment of nonobstructive disease, in addition to traditional risk factors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39503653/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39503653</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.049>10.1016/j.jacc.2024.06.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39503653</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lisa E Vaughan</dc:creator>
<dc:creator>Yoshihisa Kanaji</dc:creator>
<dc:creator>Sonja Suvakov</dc:creator>
<dc:creator>Santosh Parashuram</dc:creator>
<dc:creator>Yvonne S Butler Tobah</dc:creator>
<dc:creator>Alanna M Chamberlain</dc:creator>
<dc:creator>Suzette J Bielinski</dc:creator>
<dc:creator>Natasa Milic</dc:creator>
<dc:creator>Rajiv Gulati</dc:creator>
<dc:creator>Karl A Nath</dc:creator>
<dc:creator>Amir Lerman</dc:creator>
<dc:creator>Vesna D Garovic</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Hypertensive Disorders of Pregnancy Increase the Risk for Myocardial Infarction: A Population-Based Study</dc:title>
<dc:identifier>pmid:39503653</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.049</dc:identifier>
</item>
<item>
<title>Valve Choice for TAVR: Much Left to re-SOLVE</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39503652/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 25:S0735-1097(24)09796-1. doi: 10.1016/j.jacc.2024.09.1216. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39503652/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39503652</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1216>10.1016/j.jacc.2024.09.1216</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39503652</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Neel M Butala</dc:creator>
<dc:creator>Amar Krishnaswamy</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Valve Choice for TAVR: Much Left to re-SOLVE</dc:title>
<dc:identifier>pmid:39503652</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1216</dc:identifier>
</item>
<item>
<title>Effect of Valve Type and Anesthesia Strategy for TAVR: 5-Year Results of the SOLVE-TAVI Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39503651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Transfemoral TAVR using either SEV and BEV as well as CS and GA showed similar clinical outcomes at 5 years using a combined clinical endpoint.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)08456-0. doi: 10.1016/j.jacc.2024.09.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the randomized SOLVE-TAVI (compariSon of secOnd-generation seLf-expandable vs. balloon-expandable Valves and gEneral vs. local anesthesia in Transcatheter Aortic Valve Implantation) trial comparing newer-generation self-expanding valves (SEV) and balloon-expandable valves (BEV), as well as conscious sedation (CS) and general anesthesia (GA), clinical outcomes were similar both for valve and anesthesia comparison at 30 days and 1 year. Prosthesis durability may affect clinical outcomes during long-term follow-up. Moreover, the impact of the anesthesia strategy on long-term clinical outcomes is unknown so far.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to compare clinical outcomes during 5-year follow-up in the randomized SOLVE-TAVI trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the randomized, multicenter, 2 × 2 factorial, open-label SOLVE-TAVI trial, 447 intermediate- to high-risk patients with severe, symptomatic aortic stenosis were randomly assigned to transfemoral transcatheter aortic valve replacement (TAVR) using either SEV (Evolut R, Medtronic) or BEV (SAPIEN 3, Edwards Lifesciences) and also to CS vs GA. Patients were followed-up for 5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During 5 years of follow-up, the combined predefined endpoint of all-cause mortality, stroke, moderate or severe paravalvular leakage, and permanent pacemaker implantation was similar in the SEV and BEV groups (67.7% vs 63.4%; HR: 0.89; 95% CI: 0.70-1.13; P = 0.34). Stroke rates at 5 years were lower in the SEV group (2.2% vs 9.6%; HR: 4.84; 95% CI: 1.65-14.18; P = 0.002). Regarding the anesthesia comparison, the primary endpoint of all-cause mortality, stroke, myocardial infarction, and acute kidney injury occurred in 51.4% in the CS group and 61.3% in the GA group (HR: 0.80; 95% CI: 0.62-1.04; P = 0.09). All-cause mortality at 5 years was lower for CS (41.5% vs 54.3%; HR: 0.70; 95% CI: 0.53-0.94; P = 0.02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Transfemoral TAVR using either SEV and BEV as well as CS and GA showed similar clinical outcomes at 5 years using a combined clinical endpoint.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39503651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39503651</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.007>10.1016/j.jacc.2024.09.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39503651</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Hans-Josef Feistritzer</dc:creator>
<dc:creator>Thomas Kurz</dc:creator>
<dc:creator>Reinhard Vonthein</dc:creator>
<dc:creator>Leonie Schröder</dc:creator>
<dc:creator>Georg Stachel</dc:creator>
<dc:creator>Ingo Eitel</dc:creator>
<dc:creator>Christoph Marquetand</dc:creator>
<dc:creator>Roza Saraei</dc:creator>
<dc:creator>Eva Kirchhof</dc:creator>
<dc:creator>Matthias Heringlake</dc:creator>
<dc:creator>Mohamed Abdel-Wahab</dc:creator>
<dc:creator>Steffen Desch</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>SOLVE-TAVI Investigators</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Valve Type and Anesthesia Strategy for TAVR: 5-Year Results of the SOLVE-TAVI Trial</dc:title>
<dc:identifier>pmid:39503651</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.007</dc:identifier>
</item>
<item>
<title>Nanomedicine-based strategies for the treatment of vein graft disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39501093/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>Autologous saphenous veins are the most frequently used conduits for coronary and peripheral artery bypass grafting. However, vein graft failure rates of 40-50% within 10 years of the implantation lead to poor long-term outcomes after bypass surgery. Currently, only a few therapeutic approaches for vein graft disease have been successfully translated into clinical practice. Building on the past two decades of advanced understanding of vein graft biology and the pathophysiological mechanisms...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 5. doi: 10.1038/s41569-024-01094-y. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Autologous saphenous veins are the most frequently used conduits for coronary and peripheral artery bypass grafting. However, vein graft failure rates of 40-50% within 10 years of the implantation lead to poor long-term outcomes after bypass surgery. Currently, only a few therapeutic approaches for vein graft disease have been successfully translated into clinical practice. Building on the past two decades of advanced understanding of vein graft biology and the pathophysiological mechanisms underlying vein graft disease, nanomedicine-based strategies offer promising opportunities to address this important unmet clinical need. In this Review, we provide deep insight into the latest developments in the rational design and applications of nanoparticles that have the potential to target specific cells during various pathophysiological stages of vein graft disease, including early endothelial dysfunction, intermediate intimal hyperplasia and late-stage accelerated atherosclerosis. Additionally, we underscore the convergence of nanofabricated biomaterials, with a particular focus on hydrogels, external graft support devices and cell-based therapies, alongside bypass surgery to improve local delivery efficiency and therapeutic efficacy. Finally, we provide a specific discussion on the considerations, challenges and novel perspectives for the future clinical translation of nanomedicine for the treatment of vein graft disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39501093/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39501093</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01094-y>10.1038/s41569-024-01094-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39501093</guid>
<pubDate>Tue, 05 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Zhuoming Zhou</dc:creator>
<dc:creator>Wei Chen</dc:creator>
<dc:creator>Yihai Cao</dc:creator>
<dc:creator>Reza Abdi</dc:creator>
<dc:creator>Wei Tao</dc:creator>
<dc:date>2024-11-05</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Nanomedicine-based strategies for the treatment of vein graft disease</dc:title>
<dc:identifier>pmid:39501093</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01094-y</dc:identifier>
</item>
<item>
<title>Regulatory mechanisms of strigolactone perception in rice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39500324/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>Strigolactones (SLs) are hormones essential for plant development and environmental responses. SL perception requires the formation of the complex composed of an SL receptor DWARF14 (D14), F-box protein D3, and transcriptional repressor D53, triggering ubiquitination and degradation of D53 to activate signal transduction. However, mechanisms of SL perception and their influence on plant architecture and environmental responses remain elusive and controversial. Here, we report that key residues...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 2:S0092-8674(24)01157-7. doi: 10.1016/j.cell.2024.10.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Strigolactones (SLs) are hormones essential for plant development and environmental responses. SL perception requires the formation of the complex composed of an SL receptor DWARF14 (D14), F-box protein D3, and transcriptional repressor D53, triggering ubiquitination and degradation of D53 to activate signal transduction. However, mechanisms of SL perception and their influence on plant architecture and environmental responses remain elusive and controversial. Here, we report that key residues at interfaces of the AtD14-D3-ASK1 complex are essential for the activation of SL perception, discover that overexpression of the D3-CTH motif negatively regulates SL perception to enhance tillering, and reveal the importance of phosphorylation and N-terminal disordered (NTD) domain in mediating ubiquitination and degradation of D14. Importantly, low nitrogen promotes phosphorylation and stabilization of D14 to repress rice tillering. These findings reveal a panorama of the activation, termination, and regulation of SL perception, which determines the plasticity of plant architecture in complex environments.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39500324/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39500324</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.009>10.1016/j.cell.2024.10.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39500324</guid>
<pubDate>Tue, 05 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Qingliang Hu</dc:creator>
<dc:creator>Huihui Liu</dc:creator>
<dc:creator>Yajun He</dc:creator>
<dc:creator>Yanrong Hao</dc:creator>
<dc:creator>Jijun Yan</dc:creator>
<dc:creator>Simao Liu</dc:creator>
<dc:creator>Xiahe Huang</dc:creator>
<dc:creator>Zongyun Yan</dc:creator>
<dc:creator>Dahan Zhang</dc:creator>
<dc:creator>Xinwei Ban</dc:creator>
<dc:creator>Hao Zhang</dc:creator>
<dc:creator>Qianqian Li</dc:creator>
<dc:creator>Jingkun Zhang</dc:creator>
<dc:creator>Peiyong Xin</dc:creator>
<dc:creator>Yanhui Jing</dc:creator>
<dc:creator>Liquan Kou</dc:creator>
<dc:creator>Dajun Sang</dc:creator>
<dc:creator>Yonghong Wang</dc:creator>
<dc:creator>Yingchun Wang</dc:creator>
<dc:creator>Xiangbing Meng</dc:creator>
<dc:creator>Xiangdong Fu</dc:creator>
<dc:creator>Jinfang Chu</dc:creator>
<dc:creator>Bing Wang</dc:creator>
<dc:creator>Jiayang Li</dc:creator>
<dc:date>2024-11-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Regulatory mechanisms of strigolactone perception in rice</dc:title>
<dc:identifier>pmid:39500324</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.009</dc:identifier>
</item>
<item>
<title>Spatial transcriptomic landscape unveils immunoglobin-associated senescence as a hallmark of aging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39500323/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>To systematically characterize the loss of tissue integrity and organ dysfunction resulting from aging, we produced an in-depth spatial transcriptomic profile of nine tissues in male mice during aging. We showed that senescence-sensitive spots (SSSs) colocalized with elevated entropy in organizational structure and that the aggregation of immunoglobulin-expressing cells is a characteristic feature of the microenvironment surrounding SSSs. Immunoglobulin G (IgG) accumulated across the aged...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 2:S0092-8674(24)01201-7. doi: 10.1016/j.cell.2024.10.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">To systematically characterize the loss of tissue integrity and organ dysfunction resulting from aging, we produced an in-depth spatial transcriptomic profile of nine tissues in male mice during aging. We showed that senescence-sensitive spots (SSSs) colocalized with elevated entropy in organizational structure and that the aggregation of immunoglobulin-expressing cells is a characteristic feature of the microenvironment surrounding SSSs. Immunoglobulin G (IgG) accumulated across the aged tissues in both male and female mice, and a similar phenomenon was observed in human tissues, suggesting the potential of the abnormal elevation of immunoglobulins as an evolutionarily conserved feature in aging. Furthermore, we observed that IgG could induce a pro-senescent state in macrophages and microglia, thereby exacerbating tissue aging, and that targeted reduction of IgG mitigated aging across various tissues in male mice. This study provides a high-resolution spatial depiction of aging and indicates the pivotal role of immunoglobulin-associated senescence during the aging process.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39500323/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39500323</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.019>10.1016/j.cell.2024.10.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39500323</guid>
<pubDate>Tue, 05 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Shuai Ma</dc:creator>
<dc:creator>Zhejun Ji</dc:creator>
<dc:creator>Bin Zhang</dc:creator>
<dc:creator>Lingling Geng</dc:creator>
<dc:creator>Yusheng Cai</dc:creator>
<dc:creator>Chao Nie</dc:creator>
<dc:creator>Jiaming Li</dc:creator>
<dc:creator>Yuesheng Zuo</dc:creator>
<dc:creator>Yuzhe Sun</dc:creator>
<dc:creator>Gang Xu</dc:creator>
<dc:creator>Beibei Liu</dc:creator>
<dc:creator>Jiaqi Ai</dc:creator>
<dc:creator>Feifei Liu</dc:creator>
<dc:creator>Liyun Zhao</dc:creator>
<dc:creator>Jiachen Zhang</dc:creator>
<dc:creator>Hui Zhang</dc:creator>
<dc:creator>Shuhui Sun</dc:creator>
<dc:creator>Haoyan Huang</dc:creator>
<dc:creator>Yiyuan Zhang</dc:creator>
<dc:creator>Yanxia Ye</dc:creator>
<dc:creator>Yanling Fan</dc:creator>
<dc:creator>Fangshuo Zheng</dc:creator>
<dc:creator>Jinghao Hu</dc:creator>
<dc:creator>Baohu Zhang</dc:creator>
<dc:creator>Jingyi Li</dc:creator>
<dc:creator>Xin Feng</dc:creator>
<dc:creator>Feng Zhang</dc:creator>
<dc:creator>Yuan Zhuang</dc:creator>
<dc:creator>Tianjie Li</dc:creator>
<dc:creator>Yang Yu</dc:creator>
<dc:creator>Zhaoshi Bao</dc:creator>
<dc:creator>Sipei Pan</dc:creator>
<dc:creator>Concepcion Rodriguez Esteban</dc:creator>
<dc:creator>Zhili Liu</dc:creator>
<dc:creator>Haohao Deng</dc:creator>
<dc:creator>Feng Wen</dc:creator>
<dc:creator>Moshi Song</dc:creator>
<dc:creator>Si Wang</dc:creator>
<dc:creator>Guodong Zhu</dc:creator>
<dc:creator>Jiayin Yang</dc:creator>
<dc:creator>Tao Jiang</dc:creator>
<dc:creator>Weihong Song</dc:creator>
<dc:creator>Juan Carlos Izpisua Belmonte</dc:creator>
<dc:creator>Jing Qu</dc:creator>
<dc:creator>Weiqi Zhang</dc:creator>
<dc:creator>Ying Gu</dc:creator>
<dc:creator>Guang-Hui Liu</dc:creator>
<dc:date>2024-11-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Spatial transcriptomic landscape unveils immunoglobin-associated senescence as a hallmark of aging</dc:title>
<dc:identifier>pmid:39500323</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.019</dc:identifier>
</item>
<item>
<title>Type III interferons induce pyroptosis in gut epithelial cells and impair mucosal repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39500322/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>Tissue damage and repair are hallmarks of inflammation. Despite a wealth of information on the mechanisms that govern tissue damage, mechanistic insight into how inflammation affects repair is lacking. Here, we investigated how interferons influence tissue repair after damage to the intestinal mucosa. We found that type III, not type I or type II, interferons delay epithelial cell regeneration by inducing the upregulation of Z-DNA-binding protein 1 (ZBP1). Z-nucleic acids formed following...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 30:S0092-8674(24)01158-9. doi: 10.1016/j.cell.2024.10.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Tissue damage and repair are hallmarks of inflammation. Despite a wealth of information on the mechanisms that govern tissue damage, mechanistic insight into how inflammation affects repair is lacking. Here, we investigated how interferons influence tissue repair after damage to the intestinal mucosa. We found that type III, not type I or type II, interferons delay epithelial cell regeneration by inducing the upregulation of Z-DNA-binding protein 1 (ZBP1). Z-nucleic acids formed following intestinal damage are sensed by ZBP1, leading to caspase-8 activation and the cleavage of gasdermin C (GSDMC). Cleaved GSDMC drives epithelial cell death by pyroptosis and delays repair of the large or small intestine after colitis or irradiation, respectively. The type III interferon/ZBP1/caspase-8/GSDMC axis is also active in patients with inflammatory bowel disease (IBD). Our findings highlight the capacity of type III interferons to delay gut repair, which has implications for IBD patients or individuals exposed to radiation therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39500322/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39500322</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.010>10.1016/j.cell.2024.10.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39500322</guid>
<pubDate>Tue, 05 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Kautilya K Jena</dc:creator>
<dc:creator>Julien Mambu</dc:creator>
<dc:creator>Daniel Boehmer</dc:creator>
<dc:creator>Benedetta Sposito</dc:creator>
<dc:creator>Virginie Millet</dc:creator>
<dc:creator>Joshua de Sousa Casal</dc:creator>
<dc:creator>Hayley I Muendlein</dc:creator>
<dc:creator>Roberto Spreafico</dc:creator>
<dc:creator>Romain Fenouil</dc:creator>
<dc:creator>Lionel Spinelli</dc:creator>
<dc:creator>Sarah Wurbel</dc:creator>
<dc:creator>Chloé Riquier</dc:creator>
<dc:creator>Franck Galland</dc:creator>
<dc:creator>Philippe Naquet</dc:creator>
<dc:creator>Lionel Chasson</dc:creator>
<dc:creator>Megan Elkins</dc:creator>
<dc:creator>Vanessa Mitsialis</dc:creator>
<dc:creator>Natália Ketelut-Carneiro</dc:creator>
<dc:creator>Katlynn Bugda Gwilt</dc:creator>
<dc:creator>Jay R Thiagarajah</dc:creator>
<dc:creator>Hai-Bin Ruan</dc:creator>
<dc:creator>Zhaoyu Lin</dc:creator>
<dc:creator>Egil Lien</dc:creator>
<dc:creator>Feng Shao</dc:creator>
<dc:creator>Janet Chou</dc:creator>
<dc:creator>Alexander Poltorak</dc:creator>
<dc:creator>Jose Ordovas-Montanes</dc:creator>
<dc:creator>Katherine A Fitzgerald</dc:creator>
<dc:creator>Scott B Snapper</dc:creator>
<dc:creator>Achille Broggi</dc:creator>
<dc:creator>Ivan Zanoni</dc:creator>
<dc:date>2024-11-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Type III interferons induce pyroptosis in gut epithelial cells and impair mucosal repair</dc:title>
<dc:identifier>pmid:39500322</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.010</dc:identifier>
</item>
<item>
<title>Advances in the treatment of hypertrophic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39498865/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 5:ehae710. doi: 10.1093/eurheartj/ehae710. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39498865/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39498865</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae710>10.1093/eurheartj/ehae710</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39498865</guid>
<pubDate>Tue, 05 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-11-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Advances in the treatment of hypertrophic cardiomyopathy</dc:title>
<dc:identifier>pmid:39498865</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae710</dc:identifier>
</item>
<item>
<title>Dendritic cell mineralocorticoid receptor controls blood pressure by regulating T helper 17 differentiation: role of the Plcβ1/4-Stat5-NF-κB pathway</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39498862/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Dendritic cell MR plays important roles in the pathogenesis of hypertension by regulating Th17 through Plcβ1/4-Stat5-NF-κB signalling, and blockade of DC MR is beneficial for treating hypertension.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 5:ehae670. doi: 10.1093/eurheartj/ehae670. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Dendritic cells (DCs) are closely related to blood pressure (BP) regulation. Mineralocorticoid receptor (MR) is an important drug target for antihypertensive treatment. However, the role of DC MR in the pathogenesis of hypertension has not been fully elucidated. This study aimed to determine the role of DC MR in BP regulation and to explore the mechanism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Renal biopsy and peripheral blood samples were collected from hypertensive patients (HTN) for immunostaining and flow cytometry. Dendritic cell MR knockout (DCMRKO) mice, DC MR overexpressing (DCMROV) mice, DCMROV/IL-17A knockout (DCMROV/IL-17AKO) mice and finerenone-treated C57BL/6 mice were infused with angiotensin II (Ang II) to establish hypertensive models. Western blotting, chromatin immunoprecipitation, co-immunoprecipitation, and in vivo DC depletion or adoptive transfer were used to delineate the functional importance of DC MR in hypertension development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Mineralocorticoid receptor antagonists (spironolactone and finerenone) suppressed DC aggregation and activation, as well as hypertension in HTN and mice. Compared with littermate control (LC) mice, dendritic cell MR knockout mice had strikingly decreased BPs and attenuated target organ damage after Ang II infusion. Flow cytometry showed that DC MR deficiency mitigated Ang II-induced DC activation and T helper 17 (Th17) cell differentiation. RNA sequencing revealed that MR-deficient DCs had elevated expression of Plcβ1 and Plcβ4, knockdown of which reversed the inhibitory effect of MR deficiency on DC activation and Th17 differentiation. Adoptive transfer of MR-deficient DCs protected Ang II-induced hypertension, whereas knockdown of Plcβ1/4 eliminated the protective effects. At the molecular level, MR negatively regulated Plcβ1/4, which recruited SHP-1 to inactivate of Stat5 activity, resulting in enhanced NF-κB activation and Th17 polarization. Furthermore, DCMROV mice manifested more elevated BPs and target organ damage than control mice after Ang II infusion, and these differences were abolished in DCMROV/IL-17AKO mice. Finally, MR antagonists decreased the aggregation of Th17 in HTN and mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Dendritic cell MR plays important roles in the pathogenesis of hypertension by regulating Th17 through Plcβ1/4-Stat5-NF-κB signalling, and blockade of DC MR is beneficial for treating hypertension.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39498862/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39498862</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae670>10.1093/eurheartj/ehae670</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39498862</guid>
<pubDate>Tue, 05 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yong-Li Wang</dc:creator>
<dc:creator>Hong Zhu</dc:creator>
<dc:creator>Yi-Tong Pan</dc:creator>
<dc:creator>Da Shang</dc:creator>
<dc:creator>Lin-Juan Du</dc:creator>
<dc:creator>Lan Bai</dc:creator>
<dc:creator>Shi-Wei Zhu</dc:creator>
<dc:creator>Wen-Zhen Lin</dc:creator>
<dc:creator>Xing-Yu Zhang</dc:creator>
<dc:creator>Hai-Xia Lu</dc:creator>
<dc:creator>Chao Bi</dc:creator>
<dc:creator>Yuan Liu</dc:creator>
<dc:creator>Yan Liu</dc:creator>
<dc:creator>Hui Xiao</dc:creator>
<dc:creator>You-Cun Qian</dc:creator>
<dc:creator>Bin Zhou</dc:creator>
<dc:creator>Ruo-Gu Li</dc:creator>
<dc:creator>Sheng-Zhong Duan</dc:creator>
<dc:date>2024-11-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dendritic cell mineralocorticoid receptor controls blood pressure by regulating T helper 17 differentiation: role of the Plcβ1/4-Stat5-NF-κB pathway</dc:title>
<dc:identifier>pmid:39498862</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae670</dc:identifier>
</item>
<item>
<title>Transseptal Transcatheter Valve-in-Valve Mitral Valve Implantation: Ready for Prime Time</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 5;150(19):1505-1507. doi: 10.1161/CIRCULATIONAHA.124.071666. Epub 2024 Nov 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39495840</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071666>10.1161/CIRCULATIONAHA.124.071666</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495840</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Marina Urena</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Transseptal Transcatheter Valve-in-Valve Mitral Valve Implantation: Ready for Prime Time</dc:title>
<dc:identifier>pmid:39495840</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071666</dc:identifier>
</item>
<item>
<title>Letter by Zhao et al Regarding Article, "Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241106195101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 5;150(19):e348-e349. doi: 10.1161/CIRCULATIONAHA.124.071245. Epub 2024 Nov 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241106195101&v=2.18.0.post9+e462414">39495839</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071245>10.1161/CIRCULATIONAHA.124.071245</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495839</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jing Zhao</dc:creator>
<dc:creator>Qing-Liu Li</dc:creator>
<dc:creator>Peng-Zhou Hang</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhao et al Regarding Article, "Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth"</dc:title>
<dc:identifier>pmid:39495839</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071245</dc:identifier>
</item>





























</channel>
</rss>